ASPM

Across TCGA pan-cancer cohorts, ASPM Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ASPM data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ASPM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ASPM expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

OV, UCEC, and READ are the cancer types where ASPM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.180	0.844	<.001	36	view →
UCEC	DFS	Median	All	0.819	0.610	<.001	36	view →
READ	OS	Median	IV	0.111	0.893	<.001	18	view →
COAD	OS	Median	All	0.204	0.700	<.001	17	view →
ESCA	OS	Median	All	0.317	0.707	.006	12	view →
TGCT	DFS	Median	All	0.082	0.837	<.001	6	view →
SARC	OS	Median	All	0.224	0.839	<.001	6	view →
STAD	OS	Median	III,IV	0.711	0.349	.046	4	view →
SKCM	DFS	Median	II,III,IV	0.879	0.662	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ASPM–OV (OS)

Open the OV breakdown →